(NASDAQ:IMNN), Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, analysts and those interested in advances in ovarian cancer treatment and women's health are encouraged to attend, either In-person or virtually LAWRENCEVILLE, N.J., Nov. 10, 2025 […]

(NASDAQ:BJDX), Company focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization. Patient enrollment in SYMON-II clinical trial now approximately 50% completed. Recent private placement transaction completed in October 2025; Company continues to explore further financing opportunities. ACTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) —

(NasdaqGM:BCAX), Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients expected at ESMO Asia 2025 Strong financial position with approximately $408 million in cash,

(TSX-V:MATA),(OTC US:MATAF),(Other OTC:MATAF),(Boerse Frankfurt – Freiverkehr:IU3), TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Matador Technologies Inc. (TSXV:MATA, OTCQB:MATAF, FSE:IU3) (“Matador” or the “Company“), the Bitcoin Ecosystem Company, is pleased to announce that it has closed the first tranche (the “Initial Closing“) of its previously announced secured convertible note facility (the “Facility“) with ATW Partners (the

OneMedNet Delivers on Revenue Model Promise with Palantir-Powered RWD Subscriptions: Live Feeds & AI Search GlobeNewswire November 10, 2025 MINNEAPOLIS, Nov. 10, 2025 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a leader in AI-empowered Real-World Data (RWD), today announced that it will demonstrate its next-generation iRWD(TM) platform at ISPOR Europe. Built

Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments Venus NOVA is the first product clearance from the Company's new R&D strategy GlobeNewswire November 10, 2025 TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”), a global leader in

Tyson Foods Reports Fourth Quarter And Fiscal 2025 Results Achieves Year-Over-Year Growth in Sales, Adjusted Operating Income and Adjusted EPS GlobeNewswire November 10, 2025 SPRINGDALE, Ark., Nov. 10, 2025 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world's largest food companies and a recognized leader in protein with leading brands including Tyson,

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 GlobeNewswire November 10, 2025 Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Cytokinetics,

Bluejay Therapeutics' Brelovitug (BJT-778) Monotherapy Achieved 100% Virologic Response and up to 82% Combined Endpoint of Virologic Response and ALT Normalization at Week 48 in Phase 2 Study in Chronic Hepatitis D (CHD) GlobeNewswire November 10, 2025 All brelovitug dose regimens studied were well tolerated Results will be presented at The Liver Meeting(R) 2025 of

FreightCar America, Inc. Reports Third Quarter 2025 Results GlobeNewswire November 10, 2025 Delivered 42% revenue growth year-over-year Strong gross margins of 15.1%, expansion of 80 basis points Reaffirming Adjusted EBITDA guidance for full year CHICAGO, Nov. 10, 2025 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer and